Literature DB >> 34031919

Robust estimation and variable selection for the accelerated failure time model.

Yi Li1, Muxuan Liang2, Lu Mao1, Sijian Wang3.   

Abstract

This article concerns robust modeling of the survival time for cancer patients. Accurate prediction of patient survival time is crucial to the development of effective therapeutic strategies. To this goal, we propose a unified Expectation-Maximization approach combined with the L1 -norm penalty to perform variable selection and parameter estimation simultaneously in the accelerated failure time model with right-censored survival data of moderate sizes. Our approach accommodates general loss functions, and reduces to the well-known Buckley-James method when the squared-error loss is used without regularization. To mitigate the effects of outliers and heavy-tailed noise in real applications, we recommend the use of robust loss functions under the general framework. Furthermore, our approach can be extended to incorporate group structure among covariates. We conduct extensive simulation studies to assess the performance of the proposed methods with different loss functions and apply them to an ovarian carcinoma study as an illustration.
© 2021 John Wiley & Sons Ltd.

Entities:  

Keywords:  Kaplan-Meier estimator; LASSO; cancer study; censored data; predictive robust regression; sparse group LASSO

Mesh:

Year:  2021        PMID: 34031919      PMCID: PMC8364878          DOI: 10.1002/sim.9042

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.497


  12 in total

1.  The accelerated failure time model: a useful alternative to the Cox regression model in survival analysis.

Authors:  L J Wei
Journal:  Stat Med       Date:  1992 Oct-Nov       Impact factor: 2.373

2.  Regularized estimation in the accelerated failure time model with high-dimensional covariates.

Authors:  Jian Huang; Shuangge Ma; Huiliang Xie
Journal:  Biometrics       Date:  2006-09       Impact factor: 2.571

3.  Doubly penalized buckley-james method for survival data with high-dimensional covariates.

Authors:  Sijian Wang; Bin Nan; Ji Zhu; David G Beer
Journal:  Biometrics       Date:  2007-08-03       Impact factor: 2.571

4.  AKT2 contributes to increase ovarian cancer cell migration and invasion through the AKT2-PKM2-STAT3/NF-κB axis.

Authors:  Bin Zheng; Li Geng; Li Zeng; Fangfang Liu; Qiaojia Huang
Journal:  Cell Signal       Date:  2018-01-31       Impact factor: 4.315

5.  Evaluating the yield of medical tests.

Authors:  F E Harrell; R M Califf; D B Pryor; K L Lee; R A Rosati
Journal:  JAMA       Date:  1982-05-14       Impact factor: 56.272

6.  The Significance of VSIG4 Expression in Ovarian Cancer.

Authors:  Jung Mi Byun; Dae Hoon Jeong; In Hak Choi; Dae Sim Lee; Mi Seon Kang; Keun Ok Jung; You Kyung Jeon; Young Nam Kim; Eun Jung Jung; Kyung Bok Lee; Moon Su Sung; Ki Tae Kim
Journal:  Int J Gynecol Cancer       Date:  2017-06       Impact factor: 3.437

7.  Variable selection in the accelerated failure time model via the bridge method.

Authors:  Jian Huang; Shuangge Ma
Journal:  Lifetime Data Anal       Date:  2009-12-16       Impact factor: 1.588

8.  VARIABLE SELECTION FOR CENSORED QUANTILE REGRESION.

Authors:  Huixia Judy Wang; Jianhui Zhou; Yi Li
Journal:  Stat Sin       Date:  2013-01-01       Impact factor: 1.261

9.  Integrated genomic analyses of ovarian carcinoma.

Authors: 
Journal:  Nature       Date:  2011-06-29       Impact factor: 49.962

10.  BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1.

Authors:  Zhenfeng Zhang; Pengfei Ma; Ying Jing; Ying Yan; Mei-Chun Cai; Meiying Zhang; Shengzhe Zhang; Huixin Peng; Zhi-Liang Ji; Wen Di; Zhenyu Gu; Wei-Qiang Gao; Guanglei Zhuang
Journal:  Theranostics       Date:  2016-01-01       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.